Drug Profile

Pazopanib - GlaxoSmithKline/Novartis

Alternative Names: 786034; Armala; Dipeptid; GW-786034; GW-786034B; Pazopanib hydrochloride; SB-786034; Votrient

Latest Information Update: 14 Jun 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator GlaxoSmithKline
Developer Charite - Universitatsmedizin Berlin; Duke University Medical Center; GlaxoSmithKline; GSK; Masonic Cancer Center; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (USA); Novartis; Samsung Medical Center; SCRI Development Innovations; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; University of California at Irvine; University of Heidelberg; University of Minnesota; University of Oxford; University of Washington; Washington University School of Medicine
Class Amines; Antineoplastics; Indazoles; Pyrimidines; Small molecules; Sulfonamides
Mechanism of Action Angiogenesis inhibitors; Platelet-derived growth factor receptor antagonists; Proto-oncogene protein b-raf inhibitors; Proto-oncogene protein c-kit inhibitors; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists; Vascular endothelial growth factor receptor-3 antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Marketed Renal cell carcinoma; Sarcoma
Phase II Acute myeloid leukaemia; Bladder cancer; Breast cancer; Cervical cancer; Cholangiocarcinoma; Endometrial cancer; Fallopian tube cancer; Gallbladder cancer; Gastric cancer; Gastrointestinal stromal tumours; Glioblastoma; Haemangiosarcoma; Liposarcoma; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Prostate cancer; Small cell lung cancer; Soft tissue sarcoma; Solid tumours; Thyroid cancer; Urogenital cancer
No development reported Colorectal cancer; Head and neck cancer; Liver cancer
Discontinued Age-related macular degeneration; Hereditary haemorrhagic telangiectasia; Inflammatory breast cancer

26 Feb 2024 Efficacy, pharmacokinetics and adverse events data from a phase I/II PAZOGLIO trial in Glioblastoma presented at the ESMO Targeted Anticancer Therapies Congress 2024 (TAT-2024)
31 Oct 2023 Launched for Renal cell carcinoma (Metastatic disease, Recurrent, Late-stage disease) in China (PO)
02 Jun 2023 Adverse events data from a phase I/II PAZOGLIO trial in Glioblastoma presented at the 59th Annual Meeting of the American Society of Clinical Oncology 2023 (ASCO-2023)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com